Quick Answer
RIGEL PHARMACEUTICALS INC reported Cash And Cash Equivalents At Carrying Value of $40.58 million for the year ending 2025.
- RIGEL PHARMACEUTICALS INC showed a decrease of -28.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from RIGEL PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $32.23 million | Q3 2010: $22.06 million | Q1 2011: $25.71 million | Q2 2011: $42.95 million | Q3 2011: $18.68 million | Q1 2012: $22.03 million | Q2 2012: $26.15 million | Q3 2012: $26.80 million | Q1 2013: $34.16 million | Q2 2013: $21.87 million | Q3 2013: $16.03 million | Q1 2014: $14.91 million | Q2 2014: $23.88 million | Q3 2014: $12.81 million | Q1 2015: $42.72 million | Q2 2015: $17.29 million | Q3 2015: $38.58 million | Q1 2016: $14.27 million | Q2 2016: $24.95 million | Q3 2016: $25.95 million | Q1 2017: $40.14 million | Q2 2017: $32.59 million | Q3 2017: $25.88 million | Q1 2018: $40.13 million | Q2 2018: $65.08 million | Q3 2018: $61.49 million | Q1 2019: $74.70 million | Q2 2019: $44.23 million | Q3 2019: $39.09 million | Q4 2019: $22.52 million | Q1 2020: $45.23 million | Q2 2020: $36.47 million | Q3 2020: $36.57 million | Q1 2021: $20.05 million | Q2 2021: $84.82 million | Q3 2021: $30.40 million | Q1 2022: $24.68 million | Q2 2022: $27.20 million | Q3 2022: $29.87 million | Q1 2023: $40.29 million | Q2 2023: $48.81 million | Q3 2023: $45.41 million | Q1 2024: $25.57 million | Q2 2024: $36.05 million | Q3 2024: $51.69 million | Q1 2025: $45.73 million | Q2 2025: $53.41 million | Q3 2025: $48.53 million.
- Over the full 18 years of available data (2008 to 2025), RIGEL PHARMACEUTICALS INC's Cash And Cash Equivalents At Carrying Value has declined by 11.8%.
- Historical annual values: Fiscal year 2025: $40.58 million | Fiscal year 2024: $56.75 million | Fiscal year 2023: $32.79 million | Fiscal year 2022: $24.46 million | Fiscal year 2021: $18.89 million | Fiscal year 2020: $30.37 million | Fiscal year 2019: $22.52 million | Fiscal year 2018: $76.32 million | Fiscal year 2017: $38.29 million | Fiscal year 2016: $17.63 million | Fiscal year 2015: $43.46 million | Fiscal year 2014: $15.20 million | Fiscal year 2013: $20.85 million | Fiscal year 2012: $33.48 million | Fiscal year 2011: $18.63 million | Fiscal year 2010: $8.88 million | Fiscal year 2009: $14.72 million | Fiscal year 2008: $46.01 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: